ha14-1 has been researched along with Diffuse Lymphocytic Lymphoma, Poorly-Differentiated in 1 studies
ethyl 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate: a BH3 mimetic; synergistic induction of apoptosis by simultaneous disruption of the Bcl-2 and MEK/MAPK pathways in acute myelogenous leukemia
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Campàs, C | 1 |
| Cosialls, AM | 1 |
| Barragán, M | 1 |
| Iglesias-Serret, D | 1 |
| Santidrián, AF | 1 |
| Coll-Mulet, L | 1 |
| de Frias, M | 1 |
| Domingo, A | 1 |
| Pons, G | 1 |
| Gil, J | 1 |
1 other study available for ha14-1 and Diffuse Lymphocytic Lymphoma, Poorly-Differentiated
| Article | Year |
|---|---|
Bcl-2 inhibitors induce apoptosis in chronic lymphocytic leukemia cells.
Topics: Antimycin A; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzopyrans; Cell Survival; | 2006 |